Transient increase in symptoms associated with cytokine release in patients with multiple sclerosis

Brain

Volumn 119, Issue 1, 1996, Pages 225-237

  Moreau, Thibault ^a   Coles, Alasdair ^a   Wing, Mark ^b   Isaacs, John ^a   Hale, Geoffrey ^a,d   Waldmann, Herman ^a,d   Compston, Alastair ^a,c  

^a UNIVERSITY OF CAMBRIDGE   (United Kingdom)

^b MEDICAL RESEARCH COUNCIL   (United Kingdom)

^c UNIVERSITY OF CAMBRIDGE   (United Kingdom)

^d UNIVERSITY OF OXFORD   (United Kingdom)

Author keywords

CAMPATH 1H; Cytokines; Lymphocytes; Multiple sclerosis; Symptoms

Indexed keywords

ALEMTUZUMAB; CYTOKINE; GAMMA INTERFERON; INTERLEUKIN 6; METHYLPREDNISOLONE; TUMOR NECROSIS FACTOR ALPHA;

ADULT; ARTICLE; CLINICAL ARTICLE; COMPLEMENT ACTIVATION; COMPLEMENT HEMOLYSIS TEST; FEMALE; HUMAN; MALE; MULTIPLE SCLEROSIS; NEUROLOGIC DISEASE; PRIORITY JOURNAL;

EID: 0029869119     PISSN: 00068950     EISSN: None     Source Type: Journal    
DOI: 10.1093/brain/119.1.225     Document Type: Article

References (50)

1. Anegon I, Cuturi MC, Trinchieri G, Perussia B. Interaction of Fc receptor (CD16) ligands induces transcription of interieukin 2 receptor (CD25) and lymphokine genes and expression of their products in human natural killer cells. J Exp Med 1988; 167: 452-72.
2. Bazzoni F, Cassatella MA, Laudanna C, Rossi F. Phagocytosis of opsonized yeast induces tumor necrosis factor-alpha mRNA accumulation and protein release by human polymorphonuclear leukocytes. J Leukoc Biol 1991; 50: 223-8.
3. Black JA, Kocsis JD, Waxman SG. Ion channel organization of the myelinated fiber. [Review]. Trends Neurosci 1990; 13: 48-54.
4. Brosnan CF, Litwak MS, Schroeder CE, Selmaj K, Raine CS, Arezzo JC. Preliminary studies of cytokine-induced functional effects on the visual pathways in the rabbit. J Neuroimmunol 1989; 25: 227-39.
5. Charpentier B, Hiesse C, Lantz O, Ferran C, Stephens S, O'Shaugnessy D, et al. Evidence that antihuman tumor necrosis factor monoclonal antibody prevents OKT3-induced acute syndrome. Transplantation 1992; 54: 997-1002.
6. Chofflon M, Juillard C, Juillard P, Gauthier G, Grau GE. Tumor necrosis factor alpha production as a possible predictor of relapse in patients with multiple sclerosis. Eur Cytokine Netw 1992; 3: 523-31.
7. Cobbold SP, Rebello PRUB, Davies HF, Friend PJ, Clark MR. A simple method for measuring patient anti-globulin responses against isotypic or idiotypic determinants. J Immunol Methods 1990; 127: 19-24.
8. Ebers GC. Treatment of multiple sclerosis. [Review]. Lancet 1994; 343: 275-9.
9. Ellison MD, Merchant RE. Appearance of cytokine-associated central nervous system myelin damage coincides temporally with serum tumor necrosis factor induction after recombinant interleukin-2 infusion in rats. J Neuroimmunol 1991; 33: 245-51.
10. Gutierrez EG, Banks WA, Kastin AJ. Murine tumor necrosis factor-alpha is transported from blood to brain in the mouse. J Neuroimmunol 1993; 47 :169-76.
11. Hafler DA, Weiner HL. Immunosuppression with monoclonal antibodies in multiple sclerosis. Neurology 1988; 38 (7 Suppl 2): 42-7.
12. Hafler DA, Fallis RJ, Dawson DM, Schlossman SF, Reinherz EL, Weiner HL. Immunologic responses of progressive multiple sclerosis patients treated with an anti-T-cell monoclonal antibody, anti-T12. Neurology 1986; 36: 777-84.
13. Hale G, Dyer MJ, Clark MR, Phillips JM, Marcus R, Riechmann L, et al. Remission induction in non-Hodgkin lymphoma with reshaped human monoclonal antibody CAMPATH-1H. Lancet 1988; 2: 1394-9.
14. Han J, Thompson P, Beutler B. Dexamethasone and pentoxifylline inhibit endotoxin-induced cachectin/tumor necrosis factor synthesis at separate points in the signaling pathway. J Exp Med 1990; 172: 391-4.
15. Hartung HP. Immune-mediated demyelination [comment]. [Review]. Ann Neurol 1993; 33: 563-7. Comment on: Ann Neurol 1993; 33: 591-6.
16. Hartung HP. Immune-mediated demyelination [comment]. [Review]. Ann Neurol 1993; 33: 563-7. Comment on: Ann Neurol 1993; 33: 591-6.
17. Hofman FM, Hinton DR, Johnson K, Merrill JE. Tumor necrosis factor identified in multiple sclerosis brain. J Exp Med 1989; 170: 607-12.
18. Isaacs JD, Watts RA, Hazleman BL, Hale G, Keogan MT, Cobbold SP, et al. Humanised monoclonal antibody therapy for rheumatoid arthritis. Lancet 1992; 340: 748-52.
19. Lindsey JW, Hodgkinson S, Mehta R, Siegel RC, Mitchell DJ, Lim M, et al. Phase I clinical trial of chimeric monoclonal anti-CD4 antibody in multiple sclerosis. Neurology 1994a; 44: 413-19
20. Lindsey JW, Hodgkinson S, Mehta R, Mitchell D, Enzmann D, Steinman L. Repeated treatment with chimeric anti-CD4 antibody in multiple sclerosis. Ann Neurol 1994b; 36: 183-9.
21. Lockwood CM, Thiru S, Isaacs JD, Hale G, Waldmann H. Long-term remission of intractable systemic vasculitis with monoclonal antibody therapy. Lancet 1993; 341: 1620-2.
22. McDonald WI. The Pathophysiology of multiple sclerosis. In: McDonald WI, Silberberg DH, editors. Multiple sclerosis. London: Butterworths, 1986: 112-33.
23. McDonald WI, Sears TA. The effects of experimental demyelination on conduction in the central nervous system. Brain 1970; 93: 583-98.
24. Moreau T, Thorpe J, Miller D, Moseley I, Hale G, Waldmann H, et al. Preliminary evidence from magnetic resonance imaging for reduction in disease activity after lymphocyte depletion in multiple sclerosis [published erratum appears in Lancet 1994; 344: 486]. Lancet 1994; 344: 298-301.
25. O'Flaherty JT, Craddock PR, Jacob HS. Mechanism of anticomplementary activity of corticosteroids in vivo: possible relevance in endotoxin shock. Proc Soc Exp Biol Med 1977; 154: 206-9.
26. Okusawa S, Yancey KB, van der Meer JWM, Endres S, Lonnemann G, Hefter K, et al. C5a stimulates secretion of tumor necrosis factor from human mononuclear cells in vitro. Comparison with secretion of interleukin 1beta and interleukin 1alpha. J Exp Med 1988; 168: 443-8.
27. Panitch HS, Hirsch RL, Haley AS, Johnson KP. Exacerbations of multiple sclerosis in patients treated with gamma interferon. Lancet 1987; 1: 893-5.
28. Peces R, Urra JM, Escalada P, Gorostidi M, Gonzalez E, Lopez-Larrea C. High-dose of methylprednisolone inhibits the OKT3-induced cytokine-related syndrome [letter]. Nephron 1993; 63: 118.
29. Plata-Salaman CR, Oomura Y, Kai Y. Tumor necrosis factor and interleukin-1beta suppression of food intake by direct action in the central nervous system. Brain Res 1988; 448: 106-14.
30. Poser CM, Paty DW, Scheinberg L, McDonald WI, Davis FA, Ebers GC, et al. New diagnostic criteria for multiple sclerosis: guidelines for research protocols. Ann Neurol 1983; 13: 227-31.
31. Racadot E, Rumbach L, Bataillard M, Galmiche J, Henlin JL, Truttmann M, et al. Treatment of multiple sclerosis with anti-CD4 monoclonal antibody. A preliminary report on B-F5 in 21 patients. J Autoimmun 1993; 6: 771-86.
32. Riechmann L, Clark M, Waldmann H, Winter G, et al. Reshaping human antibodies for therapy. Nature 1988; 332: 323-7.
33. Sawada M, Hara N, Maeno T. Extracellular tumor necrosis factor induces a decreased K+ conductance in an identified neuron of Aplysia kurodai. Neurosci Lett 1990; 115: 219-25.
34. Sawada M, Hara N, Maeno T. Analysis of a decreased Na+ conductance by tumor necrosis factor in identified neuron of Aplysia kurodai. J Neurosci Res 1991; 28: 466-73.
35. Sharief MK, Hentges R. Association between tumor necrosis factor alpha and disease progression in patients with multiple sclerosis [see comments]. N Engl J Med 1991; 325: 467-72.
36. Schauf CL, Davis FA. Impulse conduction in multiple sclerosis: a theoretical basis for modification by temperature and pharmacological agents. J Neurol Neurosurg Psychiatry 1974; 37: 152-61.
37. Schermuck S, Burger R. C3a and C3a-desArg induce release of IL-6 and TNFa from human monocytes [abstract]. Mol Immunol 1993; 30 Suppl 1: 50.
38. Sears TA, Bostock H, Sheratt M. The pathophysiology of demyelination and its implications for the symptomatic treatment of multiple sclerosis. Neurology 1978; 28 (9 Pt 2): 21-6.
39. Selmaj KW, Raine CS. Tumor necrosis factor mediates myelin and oligodendrocyte damage in vitro. Ann Neurol 1988; 23: 339-46.
40. Soliven B, Albert J. Tumor necrosis factor modulates Ca2+ currents in cultured sympathetic neurons. J Neurosci 1992; 12: 2665-71.
41. Stein M, Gordon S. Regulation of tumor necrosis factor (TNF) release by murine peritoneal macrophages: role of cell stimulation and specific phagocytic plasma membrane receptors. Eur J Immunol 1991; 2: 431-7.
42. Uhthoff W. Untersuchungen über die bei der multiplen Herdsklerose vorkommenden Augenstörungen. Arch f Psychiat Berl 1889; 21: 55-116.
43. Urra JM, Peces R, Martinez-Naves E, Gutierrez V, Setien F, Lopez-Larrea C. Tumor necrosis factor alpha is released by monocytes in OKT3 monoclonal antibody immunosuppressive therapy. Transplant Proc 1992; 24: 2542-44.
44. Waage A, Slupphaug G, Shalaby R. Glucocorticoids inhibit the production of IL6 from monocytes, endothelial cells and fibroblasts. Eur J Immunol 1990; 20: 2439-43.
45. Waldmann H, Polliak A, Hale G, Or R, Cividalli G, Weiss L, et al. Elimination of graft-versus-host disease by in-vitro depletion of alloreactive lymphocytes with a monoclonal rat anti-human lymphocyte antibody (CAMPATH-1). Lancet 1984; 2: 483-6.
46. Waxman SG, Ritchie JM. Organization of ion channels in the myelinated nerve fiber. Science 1985; 228: 1502-7.
47. Weinshenker BG, Bass B, Karlik S, Ebers GC, Rice GP. An open trial of OKT3 in patients with multiple sclerosis. Neurology 1991; 41: 1047-52.
48. Xia MQ, Hale G, Lifely MR, Ferguson MA, Campbell D, Packman L, et al. Structure of the CAMPATH-1 antigen, a glycosyl-phosphatidylinositol-anchored glycoprotein which is an exceptionally good target for complement lysis. Biochem J 1993; 293: 633-40.
49. Youl BD, Turano G, Miller DH, Towell AD, MacManus DG, Moore SG, et al. The pathophysiology of acute optic neuritis: an association of gadolinium leakage with clinical and electrophysiological deficits. Brain 1991; 114: 2437-50.
50. Zajicek JP, Wing M, Scolding NJ, Compston DA. Interactions between oligodendrocytes and microglia: a major role for complement and tumour necrosis factor in oligodendrocyte adherence and killing. Brain 1992; 115: 1611-31.